BioPharma DiveOriginal article
New data could widen use of AstraZeneca, Amgen immune disease drug
Data ReadoutpositiveTezspirePositive
AI Analysis
Summary
Tezspire, co-developed by AstraZeneca and Amgen, succeeded in a clinical study for eosinophilic esophagitis, potentially becoming the drug's third approved indication and representing a blockbuster opportunity.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Tezspire succeeded in a study in eosinophilic esophagitis
Importance:7/10
Sentiment:
0.80
immunologyeosinophilic esophagitisindication expansionrare disease
Read the original article
Published by BioPharma Dive on August 27, 2026 3:58 PM